Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
D. F. Udwadia, D. A. Agrawal, D. Almeida, C. Rodrigues, A. Mehta (Bombay, India). Increasing incidence of fluoroquinolone resistant tuberculosis in Bombay. Eur Respir J 2005; 26: Suppl. 49, 4463

Member's Comments

No comment yet.

Related content which might interest you: The prevalence of pyrazinamide resistance in multidrug resistant tuberculosis cases in the Netherlands Source: Annual Congress 2012 - Microbiological advances in the diagnosis of tuberculosis Year: 2012 Recent transmission of drug resistant M. tuberculosis in Latvia Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis Year: 2005 Shortened multidrug-resistant tuberculosis treatment in settings with a high prevalence of ofloxacin resistance Source: Eur Respir J, 50 (1) 1700598; 10.1183/13993003.00598-2017 Year: 2017 Prevalence of aminoglycoside resistance among different MDR tuberculosis cases in Ukraine Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 High incidence of the Beijing strains among multi drug resistance isolates of Mycobacterium tuberculosis from extra pulmonary tuberculosis cases in northern India Source: Annual Congress 2012 - Non-tuberculous and tuberculous mycobacterial infections: from epidemiology to clinical findings Year: 2012 Extensively drug resistant tuberculosis (XDR TB) in a high income country: a report of four unrelated cases Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 Drug resistance profiles of mycobacterium tuberculosis isolates in MDR pulmonary tuberculosis from a high burden developing country Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Molecular surveillance of multi-drug resistant tuberculosis in Europe Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 Strategies against multidrug-resistant tuberculosis Source: Eur Respir J 2002; 20: 66S-77S Year: 2002 Treatment of TB Source: Eur Respir Mon 2012; 58: 154-166 Year: 2012 Our experience in multi drug resistant tuberculosis (MDR TB) treatment Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005 Multi-drug resistant tuberculosis (MDR-TB) in Ramnicul Valcear, Romania; drug treatment, resistance testing and adverse drug reactions Source: Eur Respir J 2006; 28: Suppl. 50, 378s Year: 2006 A 10-year prospective surveillance of Mycobacterium tuberculosis drug resistance in France 1995 2004 Source: Eur Respir J 2007; 30: 937-944 Year: 2007 Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB Source: Eur Respir J 2009; 33: 581-585 Year: 2009 Treatment of multidrug resistant pulmonary tuberculosis (MDR-TB) with different pattern of resistance Source: Eur Respir J 2004; 24: Suppl. 48, 723s Year: 2004 Frequency of side effects among patients with drug resistant tuberculosis (DR-TB) by resistance pattern in a high burden country. Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Low prevalence of fluoroquinolone resistance among patients with tuberculosis in the Philippines: results of a national survey Source: Eur Respir J, 51 (3) 1702571; 10.1183/13993003.02571-2017 Year: 2018 Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases Source: Eur Respir J 2008; 31: 1155-1159 Year: 2008 High risk and rapid appearance of multidrug resistance during tuberculosis treatment in Moldova Source: Eur Respir J 2014; 43: 1132-1141 Year: 2014 Fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis independent of fluoroquinolone use Source: Eur Respir J, 50 (6) 1701633; 10.1183/13993003.01633-2017 Year: 2017